One of the three R's is under scrutiny
Sen. Marco Rubio (R-Fla.) and Rep. Tim Griffin (R-Ark.) are introducing bills in the Senate and House to repeal the rule under the Affordable Care Act (ACA) that creates risk corridors in the exchange marketplaces.
Even though insurers themselves contribute to the fund that helps equalize risk during start-up years, the lawmakers believe the government’s share is a burden on tax payers and they have some support, according to The Hill.
While risk adjustment is a permanent feature in the exchanges, risk corridors and the reinsurance mechanism are temporary and help prevent the so-called “death spiral,” which could drive an insurer out of market if it ended up with a disproportionate share of high-risk enrollees.
"The ACA's risk management programs are intended to protect consumers by helping to create a stable marketplace environment during the initial years of the law's implementation,” Clare Krusing, spokesperson for America’s Health Insurance Plans, tells MHE.
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More